Lower riskDrug recall · FDA · Published March 17, 2022
Aurolife Glycopyrrolate Tablets Recall: Glass Pieces Found in Sealed Bottles
Aurolife Pharma recalls 1 mg Glycopyrrolate tablets due to glass fragments in sealed bottles. This risk requires immediate action to avoid potential injury.
“Aurolife Glycopyrrolate Tablets Recall: Glass Pieces Found in Sealed Bottles.” GovInfoNow, updated August 18, 2026. https://govinfonow.com/recall/35074-aurolife-glycopyrrolate-tablets-recall-glass-pieces-found-in-sealed-bottles. Based on FDA recall #D-0736-2022 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0736-2022%22&limit=1).
The FDA announced on March 17, 2022, that Aurolife Pharma, LLC is recalling Glycopyrrolate Tablets, USP, 1 mg due to the presence of glass fragments. The agency classified the recall as Class II.
Distribution: Nationwide in the USA and Puerto Rico
The hazard
The recall addresses complaints of pieces of glass discovered in a sealed bottle, which originated from equipment within the packaging room. The FDA stated this foreign substance poses a risk to consumers.
Context
GovInfoNow's records show Aurolife Pharma, LLC has issued three other recalls since August 23, 2019. Recent similar recalls include an Aurolife Glycopyrrolate Tablets recall on May 18, 2023, and another on December 16, 2022, both citing failed impurities or degradation specifications. Other recent recalls of similar products include Guardian Drug CAREone Calcium Antacid Recall (May 28, 2026), Guardian HyVee Antacid Tablets Recall (May 28, 2026), and Guardian Drug recalls EQUALINE antacid tablets with metal particles (May 28, 2026).
How to tell if you have this one
Check for the 100-count bottle labeled 'Glycopyrrolate Tablets, USP, 1 mg' with NDC 13107-014-01. The lot number 01421008A1 was produced for this recall.
Brand
Aurolife
Category
Drug
Based on the official FDA remedy
What to do — step by step
Check for Glass Fragments
Inspect the bottle for any glass pieces before use. If found, stop using the tablets immediately.
Where it went and when
Where it was distributed
Distributed nationwide.
Nationwide
Not listed
FDA distribution: “Nationwide in the USA and Puerto Rico” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 2 years after the firm started it.
1Firm started the recall
2FDA classified it Class II
3Published in FDA’s Enforcement Report
4FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-0736-2022 (March 17, 2022) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0736-2022 to see it in context.
Plain-language summary written by qwen3:4b on August 18, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.